Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04570631 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT04570631
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04570631 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Terminated
Start date
November 5, 2020
Completion date
May 5, 2025
Enrollment
4 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma